ABSTRACT
Although the incidence and mortality of gastric cancer have been decreasing, it is still the second most common cancer after lung cancer worldwide 1 and the second most common cause of death from cancer in Asia. 2 Examination by upper gastrointestinal series or endoscopy appears to be the most accurate method for detecting gastric cancer. The detection of gastric cancer by endoscopy is approximately 4 times higher than barium studies or photofluorography. 3 Despite high detection rates, endoscopy also has shortcomings, such as the skills of the examiner, the availability of a gastroscope, and the associated expense. 3 Recently, analysis of molecular markers and protein components of gastric juice has been continued to enhance the detection rates of gastric cancer. 4-7 a 1 -Antitrypsin precursor, microRNA, methylation markers, and aromatic acids have been studied as potential biomarkers for gastric cancer. We investigated melanoma-associated gene (MAGE) expression rates in gastric cancer. Pepsinogen (PG) is well known as a gastric cancer marker in the blood. Thus, we selected MAGE and PG as candidates for gastric cancer biomarkers in gastric juice.
Melanoma-associated gene is a cancer-specific marker that suppresses apoptosis and plays an important role in carcinogenesis. 8 In our previous study, MAGE A1 to A6 expression was 65.2%, with a 4.3% false-positive rate. 9 Interestingly, Helicobacter pylori induced the expression of MAGE in a MAGE-negative cancer cell line but not in normal cells. 10 Pepsinogen, a precursor of pepsin, exists as 2 main types (PG I and II) that are potent and abundant digestive enzymes secreted by the gastric chief cells as a proenzyme, then converted in the stomach lumen to the active enzyme pepsin by hydrochloric acid in gastric juice. 11, 12 As atrophic gastritis becomes more severe, normal gland function is lost and enzyme production is affected. The concentration of PG reflects the morphologic and functional status of the gastric mucosa. 13, 14 Many gastric cancers that develop in the stomach mucosa are affected by severe and extensive chronic atrophic gastritis. 15 Therefore, PG analysis facilitates detection in those with extensive atrophic gastritis who have a high risk of developing gastric cancer. 16 Since the 1990s in Japan, the test for serum PG as a marker for chronic atrophic gastritis has been incorporated into gastric cancer screening programs, and numerous centers have measured serum PG levels as part of gastric cancer screening. 17 Dinis-Ribeiro et al 18 performed a meta-analysis of the sensitivity and specificity results from 27 population-based screening studies. In this meta-analysis, the PG I level was 70 ng/mL or less and the PG I/II ratio was 3 or less, with a sensitivity of 77% and a false-positive rate of 27%.
The proenzymes of PG are mainly excreted into the stomach lumen, but a very low portion (approximately 1%) backdiffuses into the bloodstream. 17 It therefore might be expected that PG analysis of gastric juice to detect gastric cancer would be more accurate than serum.
This study was designed to determine if a combination test of PG and MAGE RNA in gastric juice could be used as an additional or novel tool for detecting gastric cancer. In the literature review, we found that our PG analysis in gastric juice might be the first trial for gastric cancer detection. We also examined the characteristics detected and missed by gastric juice analysis in patients with gastric cancer.
Materials and Methods

Patients
In total, 183 gastric juice specimens were obtained from 49 consecutive healthy participants and 134 patients who underwent surgery for gastric cancer in the Department of Surgery at Catholic University Medical Center of Daegu between October 2008 and January 2010. The control group that was recruited from our health examination clinics had no clinical history of gastrointestinal diseases, and the endoscopic findings were normal. Patients in the cancer group had their gastric cancer confirmed by endoscopic examination and subsequently underwent radical gastrectomies, and an expert pathologist did histologic examinations of the resected specimens. We identified 49 samples from the cancer group that were age and sex matched with the control group. The study design was approved by the institutional review board of the Catholic University Medical Center of Daegu, and informed consent was obtained from all participants.
Serum and Gastric Juice Collection
Fasting serum was collected from all individuals at study entry. In the healthy participants, gastric juice samples (8-10 mL) were obtained during endoscopic examination in the fasting state (10-15 hours) to analyze PG concentrations and MAGE expression. Gastric juice samples from the gastric cancer group were also obtained in the fasting state (10-15 hours). In patients who had a distal gastrectomy, we obtained the gastric juice samples using a catheter and syringe after opening the gastric wall in the operative field at the end of the surgical procedure, but in patients who had a total gastrectomy, we collected the samples from the resected specimen postoperatively. The gastric juice fluids obtained were equally divided into 2 separate tubes for PG analysis and MAGE nested reverse transcription (RT)-polymerase chain reaction (PCR) containing guanidine isothiocyanate buffer. The tubes collected from the control and cancer groups were arbitrarily marked with the test number to blind participant researchers and then transported to the laboratory.
Gastric Juice and Serum PG Analysis
One expert researcher (C.-H.J.) mixed the obtained gastric juice specimens thoroughly, and then the supernatant was transferred to a new tube for PG measurement while a tube for MAGE RT-PCR was stored with the same tube. All tubes were stored in a -70°C freezer until 20 specimens had been collected. Analysis of PG and MAGE was performed by 2 technicians well trained in the techniques. To measure PG in gastric juice specimens, we calculated calibration curves for PG I and II using ARCHITECT PG I and II reagents (Abbott, Weisbaden, Germany) and an ARCHITECT i2000 immunoassay analyzer (Abbott, Abbott Park, IL). A 2-fold serial dilution of gastric juice was made from 40 to 1,280 dilutions using phosphate-buffered saline. Linearity was maintained from 320-to 1,280-fold dilutions ❚Figure 1❚, and thus we started PG measurement at a 640-fold dilution. Concentrations of PG were measured according to the instruction manual of the ARCHITECT PG I and II reagents and the ARCHITECT System Operations Manual. If the measured concentrations were out of the analytical range, we repeated the measurements with 320-or 1,280-fold diluted specimens. Serum samples were directly measured with the same reagent and instrument.
MAGE Nested RT-PCR
From free cancer cells in the gastric juice, MAGE messenger RNA was extracted with an RNA extraction kit by using magnetic capture beads (iC&G, Daegu, Republic of Korea). RNA purities and concentrations were measured by spectrophotometry (DU530; Beckman Coulter, Brea, CA). We amplified MAGE using the nested RT-PCR kit with a common primer for MAGE A1 to A6 (iC&G). The glyceraldehyde phosphodehydrogenase gene was coamplified for verification of the entire process.
Statistical Analysis
All statistical analyses were performed using SPSS software (Windows version 14.0; SPSS, Chicago, IL) and MedCalc software (version 11.5, MedCalc, Ostend, Belgium). Null hypotheses of no difference were rejected if P values were less than .05. Before performing statistical analysis, we controlled age and sex among baseline characteristics in the cancer group. To obtain 49 samples from the cancer group that were age and sex matched with the control group, we used a resampling method using the R statistical program (R Foundation for Statistical Computing, Vienna, Austria) until there was no age and sex difference between the cancer and control groups. Quantitative and qualitative variables were summarized as the mean with standard deviation and frequency with percentile, respectively. For all diagnostic evaluations, we used receiver operating characteristic (ROC) curve analysis to find the optimum cutoff levels, calculate an appropriate sensitivity and specificity, and compare diagnoses.
Results
Demographic Characteristics of Patients and PG and MAGE Results
In total, 134 patients with gastric cancer and 49 healthy individuals were enrolled. The enrolled patients included 78 men and 56 women with a mean ± SD age of 61.4 ± 11.8 years. The control participants included 25 men and 24 women with a mean ± SD age of 46.7 ± 8.8 years. Before performing statistical analysis, we controlled age and sex among baseline characteristics in the cancer group. The demographic characteristics of the 98 age-and sex-matched participants are summarized in ❚Table 1❚. There was no significant difference between the control and gastric cancer groups with respect to age and sex for serum (s) PG II and gastric (g) PG II, while the difference with respect to the sPG I/II ratio, gPG I, and gPG I/II ratio were statistically different (P < .001). The sPG I concentrations were slightly different between the control and gastric cancer groups (P < .05). The rate of expression of MAGE in gastric juice was also statistically different (P < .001; Table 1 ).
Comparison of Diagnostic Parameters Between Serum and Gastric Juice PG Analysis
❚Table 2❚ shows a comparison of diagnostic parameters between serum and gastric juice PG concentrations in detecting gastric cancer. The gPG I and gPG I/II ratio were more accurate than the sPG I and sPG I/II ratio for the detection of gastric cancer (P = .006 and .05). Among the PG tests, the gPG I/II was the most suitable for detecting gastric cancer, but there was no statistical difference between the gPG I and gPG I/II ratio for the detection of gastric cancer (P = .68).
Evaluation of Diagnostic Parameters in Gastric Juice
Sensitivity for PG I/II and MAGE expression in gastric juice was 61.2% (PG I/II) and 53.1% (MAGE), while specificity was 91.8% (PG I/II) and 95.9% (MAGE) ❚Table 3❚. In the ROC analysis of diagnostic tests, the combination test of MAGE and the PG I/II ratio was the most accurate, with a sensitivity of 77.6%, a specificity of 87.8%, and an AUC of 0.827 for the detection of gastric cancer.
Association Between Clinicopathologic Factors and Gastric Juice Combination Test (PG I/II Ratio and MAGE)
To identify the clinical characteristics by the results of the combination test, we divided the patients with gastric cancer into 2 groups using a PG I/II ratio cutoff of 2.05 or less or MAGE expression in gastric cancer. The cutoff value of 2.05 was calculated with the ROC curve analysis. The positive cutoff was 38 patients, and the negative cutoff was 11 patients ❚Table 4❚. For the variables involved in clinicopathologic factors, there was no significant difference between the positive and negative groups, including tumor location, size, differentiation, T stage, and Lauren classification. In the 33 patients with stage I cancer, 26 (78.8%) showed positive results.
Discussion
Recent studies indicate that the development of gastric adenocarcinoma is a multistep event progressing from superficial gastritis, atrophic gastritis, intestinal metaplasia, and dysplasia to malignancy through cumulative multiple genetic changes. 19 Theoretically, there is an advantage in detecting gastric cancer with gastric juice samples since the concentration of cancer-related peptide/protein is higher than blood. 20 Noninvasive and easier diagnostic techniques to obtain gastric juice have been introduced, such as a small gelatin capsule containing a pierced plastic cover surrounding a piece of absorbent paper, 21 and a noninvasive string test. 22 These will be used to detect gastric cancer in the near future.
It is well known that the levels of sPGs, sPG I, and sPG II have been shown to be markers of a gastric mucosa functional state. 23 Among them, sPG I levels and PG I/II ratios are low in chronic atrophic gastritis, which is believed to be an important risk factor for the development of gastric carcinoma. 12 However, there are several limitations of the PG test. A decrease in PG I and the PG I/II ratio suggests the presence of atrophic gastritis, and thus the PG assay would overlook patients with cancer who did not have atrophic gastritis or had mild atrophic gastritis, 24 and therefore it would be more applicable to intestinal-type gastric cancer only. The variable results of the PG test might be related to the proportion of intestinal-type cancer in the test populations. Moreover, different cutoffs used in other studies could affect the sensitivity and specificity of results.
For this reason, we needed another marker to detect gastric cancer that is not affected by the pathologic type of cancer. In this study, we have used aspartic proteinases (PG) and a molecular marker (MAGE) in gastric juice for the screening of gastric cancer. Pepsinogen is reabsorbed and metabolized by the kidneys, so renal disease could influence the serum concentration. 11 This was another reason to regard gPG as a more accurate marker than sPG. Melanoma-associated gene has been used as a target of cancer diagnosis and tumor-specific immunotherapy due to the specific expression in tumor tissue. 25 It could be expressed in gastric carcinoma, but there is no expression of MAGE in normal gastric tissue, and no significant correlation was observed between the expression of MAGE and clinicopathologic factors. 9 This study showed that gPG I and the gPG I/II ratio analysis improved the detection accuracy compared with sPG I and the sPG I/II ratio. Also, there was a dramatic specificity improvement in the gPG I/II ratio compared with sPG I/II ratio analysis. As a diagnostic modality for cancer screening, high specificity is important to reduce false enrollment of patients for further evaluation.
Using the gastric juice specimens, the sensitivity and specificity of the gPG I/II ratio for gastric cancer were 61.2% and 91.8%, respectively, while the combination tests using MAGE expression and the PG I/II ratio improved the sensitivity (77.6%) with a slight decrease of specificity (87.8%). The combination test performed better than MAGE alone (Table  3) . Since the combination test disclosed good accuracy, it could be used as an additional tool for gastric cancer detection.
When the patients with gastric cancer were divided into 2 groups using a PG I/II ratio cutoff value (≤2.05) or MAGE expression in gastric cancer, for the variables involved in clinicopathologic factors, including pathologic types and cancer stage, there was no significant difference between the positive and negative groups. However, the combination test showed high detection rates (78.8%) for early cancer and no correlation of positive rates with cancer location and pathologic types. These findings might be important for using gPG and MAGE as an additional screening tool for gastric cancer.
Our cutoff values for sPG were different from published values. Kang et al 26 suggested using a sPG I concentration less than 70 ng/mL and a sPG I/II ratio less than 3.0 as the cutoff points, and the sensitivity and specificity of the sPG test for detecting gastric cancer in Korea were 72.4% and 20.2% at an sPG I of 70 ng/mL and 62.3% and 61.0% at an sPG I/II ratio of 3.0 or less, respectively. Although the best cutoff values of sPG I and the sPG I/II ratio for gastric cancer screening were customarily 70 ng/mL or less and 3.0 or less, respectively, the cutoff values of sPG I and the sPG I/II ratio were variable due to age, sex, height, diet, weight, nationality, circadian rhythms, and H pylori infection. 27, 28 Our cutoff values for gastric juice might be the first such results in the literature.
Endoscopy has been widely used to detect gastric cancer. Hosokawa et al 29 reported the sensitivity of endoscopy alone as 77.8%, while Tatsuta et al 30 reported the sensitivity of gastrofiberscopic biopsy as 93.8%, based on follow-up data using the cancer registry system. Due to its invasiveness, endoscopy has limited accessibility as a mass screening tool for gastric cancer. If a simple and convenient method for gastric juice collection is developed, the combination test has potential as a mass screening tool for gastric cancer. Considering the cost-effectiveness of mass screening, the gPG I/II ratio alone is recommended.
Our study has some limitations. Most important, the gastric juice was collected under conditions that differed between the control and gastric cancer groups. We obtained gastric juice with endoscopy in the control group, but for the cancer group, the gastric juice was obtained during the operation or postoperatively. To our knowledge, there has been no report of whether surgery influenced the gastric juice PG composition. The most important factor for PG composition change is the different distribution of PG I and PG II secreting cells in the stomach. 11 Alterations in their composition are correlated with pathologic changes. In conclusion, gPG analysis was more accurate than sPG analysis in detecting gastric cancer. Gastric juice analysis using PG and MAGE showed good sensitivity and specificity for the detection of gastric cancer regardless of the pathologic type and cancer stage.
